NYSEFinancialsCapital MarketsSnapshot 2026-07-31
Reading EVR? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Investment Banking & Brokerage is in expansion. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar broken — Operating income improves to at least $331 million in 2026-Q1: metric not reported.
View ThesisRevenue growth is accelerating — up about 47% over the past year.
View GrowthMiddle-of-the-pack quality for its industry.
View QualityManagement screens strong on capital allocation, margins.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationThis stock is volatile — it swings about 2% on a typical day and fell roughly 30% in its worst 12-month stretch.
View RiskEvercore's growth in private credit volume has to keep compounding to justify the price. Revenue grew 19% year over year, but the latest quarter missed expectations with an EPS of 2.91 against a target of 14.05. It trades at 16× P/E versus a peer median of 21×, indicating that the price reflects less growth than forecasted. The primary risk is the recent earnings miss, which has broken a key pillar of the thesis. Peer multiples imply a price roughly in line with where it trades; this read is provisional.
Trailing returns as of 2026-07-31. EVR is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 11 analysts currently covering EVR (as of Jul 2026).
Based on 4 Wall Street analysts offering 12-month price targets for EVR in the last 4 months.
A consensus fair price across 10 valuation methods, at three horizons. As of 2026-08-01. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Investment Banking & Brokerage — fair value, gap to price, and forward P/E.
Our valuation methods disagree too much on this name right now. Rather than print a number we don't believe, we're holding it back until they converge.
Advances: Increase revenue growth
Increased private credit volume supports revenue growth objective.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-07-31. EPS is implied from price ÷ P/E. Not investment advice.
Current $320.56
The last 12 months of price, then the range of analyst 12-month targets from today’s $320.56.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Top 10% on quality vs scored peers
A second lens on the 12-month fair value: for companies that score high on measured quality (profitability, balance-sheet safety, earnings stability), this read trusts more of today's profit margins instead of averaging them toward their multi-year history the way the headline number does. Shown alongside the fair value above, not in place of it. A diagnostic, not a price target or a buy/sell signal.
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Advances: Increase revenue growth
Price target hike indicates confidence in revenue growth potential.
Warning indicates potential revenue growth challenges.
Warning indicates potential revenue growth challenges.
Initiation with Outperform rating supports revenue growth objective.
Advances: Increase revenue growth
Deleveraging indicates improved cash flow and revenue growth potential.
Advances: Increase revenue growth
New senior hire enhances revenue growth potential.
Advances: Increase revenue growth
Senior hire in healthcare boosts investment banking capabilities.
